Voyager Therapeutics, Inc.
VYGR
$4.46
-$0.42-8.52%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 144.28% | -45.73% | -82.42% | -66.83% | -93.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 144.28% | -45.73% | -82.42% | -66.83% | -93.03% |
| Cost of Revenue | -5.71% | 18.60% | -1.95% | 16.37% | 38.15% |
| Gross Profit | 37.84% | -300.94% | -1,000.67% | -230.69% | -145.57% |
| SG&A Expenses | -8.65% | -0.92% | 3.39% | 12.00% | -12.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.30% | 14.45% | -0.66% | 15.31% | 23.83% |
| Operating Income | 30.99% | -122.02% | -192.42% | -114.38% | -170.84% |
| Income Before Tax | 19.13% | -208.95% | -229.81% | -173.81% | -159.25% |
| Income Tax Expenses | -98.46% | 93.02% | -37.50% | 164.29% | -28.95% |
| Earnings from Continuing Operations | 20.47% | -208.40% | -229.18% | -173.80% | -161.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.47% | -208.40% | -229.18% | -173.80% | -161.15% |
| EBIT | 30.99% | -122.02% | -192.42% | -114.38% | -170.84% |
| EBITDA | 31.93% | -134.52% | -219.41% | -124.72% | -167.31% |
| EPS Basic | 21.79% | -203.45% | -223.85% | -167.94% | -146.40% |
| Normalized Basic EPS | 30.62% | -204.12% | -330.91% | -168.09% | -144.96% |
| EPS Diluted | 21.34% | -196.44% | -216.67% | -165.80% | -147.68% |
| Normalized Diluted EPS | 30.62% | -204.12% | -330.91% | -168.09% | -146.07% |
| Average Basic Shares Outstanding | 1.66% | 1.65% | 1.64% | 2.16% | 31.81% |
| Average Diluted Shares Outstanding | 1.66% | 1.65% | 1.64% | 2.16% | 28.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |